文献速递贫血与红细胞疾病

口服铁剂方案对妊娠期铁生物标志物的影响:PANDA试验

Impact of oral iron dosing regimens on iron biomarkers during pregnancy: insights from the PANDA trial.
PubMed 文献 · Blood Adv · 2026-01-01

PANDA剂量探索试验纳入135例非贫血孕妇,随机接受每日、隔日或每周三次200mg硫酸亚铁,检测9-13周和26-30周铁生物标志物。所有组hepcidin、铁蛋白和转铁蛋白饱和度均显著下降,隔日和每周三次组sTfR升高而每日组无显著变化;26-30周时69%-72%妇女铁缺乏。

要点

  • 无论何种补铁方案,妊娠期铁状态均下降,生理适应可能主导剂量效应。
  • 每日补铁组sTfR无显著升高,提示每日给药可能最佳满足妊娠铁需求。
  • 26-30周时69%-72%非贫血孕妇铁蛋白<30 μg/L,仍存在铁缺乏。

核心结论

  • 妊娠期铁状态下降不受补铁方案影响,生理适应可能主导剂量效应。
  • 每日补铁组sTfR无显著升高,提示每日给药可能最佳满足妊娠铁需求,但需更大样本验证。

研究设计与样本

  • PANDA剂量探索随机对照试验,非贫血孕妇随机接受200 mg硫酸亚铁每日、隔日或每周三次。
  • 在9-13周和26-30周采集血样,共135例参与者。

主要发现

  • 所有组hepcidin、铁蛋白和转铁蛋白饱和度从基线至随访均显著下降(P< .001)。
  • sTfR在隔日组(P = .003)和每周三次组(P< .001)升高,每日组无显著变化(P = .084)。
  • 26-30周时69%至72%妇女铁缺乏(铁蛋白<30 μg/L)。

关键数值与推荐

  • 铁缺乏定义为铁蛋白<30 μg/L。
  • 补铁剂量为200 mg硫酸亚铁,方案为每日、隔日或每周三次。

临床怎么用

  • 妊娠期补铁需考虑生理性铁状态下降,每日方案可能更利于满足铁需求。
  • 即使补铁且血红蛋白维持,仍需监测铁蛋白以识别铁缺乏。

局限性

  • 样本量135例,需更大规模 adequately powered 研究确认每日给药的优越性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Iron deficiency during pregnancy remains a global health burden, yet pregnancy-related physiological adaptations complicate the interpretation of iron biomarkers. Modified oral iron regimens are increasingly used to balance iron intake, absorption, and tolerability. This study evaluated the effects of daily, alternate-day, and 3-times-weekly oral iron supplementation on iron status biomarkers in nonanaemic pregnant participants. In the PANDA (Primary prevention of maternal Anemia to avoid preterm Delivery and other Adverse outcomes) dose-finding trial, nonanemic pregnant women were randomized to receive 200 mg of ferrous sulfate daily, on alternate days, or 3-times-weekly. Blood samples were collected at 9 to 13 and 26 to 30 weeks' gestation (N = 135 participants). Hepcidin and soluble transferrin receptor (sTfR) were measured by enzyme-linked immunosorbent assay, and serum iron, ferritin, transferrin, and C-reactive protein using automated biochemistry. Linear mixed-effects models assessed within- and between-group biomarker changes. Hepcidin, ferritin, and transferrin saturation declined significantly between baseline and follow-up in all groups (P< .001). sTfR increased in the alternate-day (P = .003) and 3-times-weekly groups (P< .001), but not in the daily group (P = .084). Despite supplementation and maintenance of hemoglobin levels, 69% to 72% of women were iron deficient (ferritin <30 μg/L) at 26 to 30 weeks' gestation. Iron status declined across pregnancy regardless of supplementation regimen, suggesting physiological adaptations may dominate over dosing effects. The absence of a significant rise in sTfR in the daily group suggests that daily dosing best meets the iron demand of pregnancy, though confirmation in larger, adequately powered studies is required. This trial was registered at the UK trial registry as #ISRCTN12911644.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Haynes S, Armitage AE, Roy NBA, et al. Impact of oral iron dosing regimens on iron biomarkers during pregnancy: insights from the PANDA trial. Blood Adv. 2026. PMID: 42024457. doi:10.1182/bloodadvances.2026019740

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。